Ajai Sulekh – General Manager MART, Biogen
Biogen’s manager for the Middle East, Africa, Russia & CIS, Turkey (MART), Ajai Sulekh, discusses the company’s five-pillar strategy to expand…
Tagged with Alzheimer's
Tashia Lentz – Managing Director, Biogen Denmark
Tashia Lentz of Biogen outlines what she sees as an increasingly tough market access environment for new treatments in Denmark and calls for greater…
Aducanumab Approval: Opening the Floodgates for a New Era of…
With the US FDA’s controversial recent decision to approve Biogen and Eisai’s aducanumab – the first approval for a new Alzheimer’s disease…
If the “Primary Endpoint” in an Alzheimer’s…
Taking the example of music's effect on Alzheimer's disease patients, John G Singer makes the case for a more holistic approach to healthcare;…
Charles Stacey – President & CEO, Cerecin
Cerecin’s Charles Stacey outlines the company’s progress in expanding its lead asset into migraine and infantile spasms, how its funding strategy…
Antonella Santuccione Chadha – CEO pro-bono, Women’s…
Antonella Santuccione Chadha*, Head of Stakeholder Engagement for Alzheimer’s disease at Biogen and co-founder and CEO of the Women’s Brain…
China: Green Valley Alzheimer’s Trial; Samsung Biologics…
A roundup of the latest from Chinese pharma, including Green Valley's upcoming US trial for an Alzheimer's drug inspired by algae; Samsung Biologics…
Aducanumab edges closer to Potential Approval: Next up, the…
In his latest piece on Alzheimer’s Disease (AD) drug Aducanumab’s winding journey to market, Dr Neil Cashman looks forward to the US FDA Advisory…
Aducanumab: On the Regulatory Home Stretch in the USA
In the third of a series of articles chronicling Biogen/Eisai’s Alzheimer’s Disease (AD) treatment aducanumab’s torturous journey to market, Dr…
Ivan Cheung – Chairman, Eisai Inc.; President, Neurology…
Ivan Cheung, head of Japanese firm Eisai’s US operations, highlights the significance of a potential 2021 US FDA approval for Alzheimer’s Disease…
Opinion: The Paradigm Shift Needed for Effective Alzheimer’s…
Holmusk’s Nawal Roy outlines why a cure for Alzheimer’s Disease is the “Holy Grail” of medicine today, the reasons for so many biotech…
Luis Calderon – General Manager, Biogen Mexico
Biogen Mexico’s Luis Calderon discusses establishing the affiliate, the opportunities apparent in the Mexican neurodegenerative disease market, and…
